首页> 美国卫生研究院文献>BMC Pediatrics >Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized double-blind non-inferiority trial
【2h】

Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized double-blind non-inferiority trial

机译:儿童生命第二年中无人血清白蛋白的水痘疫苗与获得许可的水痘疫苗的比较:一项随机双盲非劣效性试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGSK’s varicella vaccine contains human serum albumin (HSA) which is used to stabilize the virus and prevent immunogens from adhering to the injection vial walls. However, because HSA is derived from human blood, there is a theoretical risk that it might contain infectious agents which could be unsafe for humans. Given this concern, a study was undertaken to compare the immunogenicity and safety of a new formulation without HSA with the currently licensed varicella vaccine in the Czech Republic and Hungary.
机译:BackgroundGSK的水痘疫苗含有人血清白蛋白(HSA),可用于稳定病毒和防止免疫原粘附到注射瓶壁上。但是,由于HSA来源于人体血液,因此从理论上讲,它可能含有可能对人体不安全的传染原。考虑到这种担忧,在捷克共和国和匈牙利进行了一项研究,以比较不含HSA的新制剂与目前许可的水痘疫苗的免疫原性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号